5 April 2018 - PHARMAC is seeking feedback on a proposal to list mercaptopurine oral solution (Allmercap) 20 mg/mL from 1 June 2018, through a provisional agreement with Link Pharmaceuticals Limited.

Mercaptopurine oral solution is considered to be a more suitable formulation of mercaptopurine, compared with the currently funded tablet formulation, for young children who require low doses for the treatment of acute lymphoblastic leukaemia.

Read PHARMAC proposal